<?xml version="1.0" encoding="UTF-8"?>
			<!DOCTYPE ijpp.edwiserinternational.com [
<!ELEMENT channel (title,link,description,language,managingEditor,webMaster,copyright,image,item,item,item,item,item)>
<!ELEMENT title (#PCDATA)>
<!ELEMENT link (#PCDATA)>
<!ELEMENT language (#PCDATA)>
<!ELEMENT managingEditor (#PCDATA)>
<!ELEMENT webMaster (#PCDATA)>
<!ELEMENT copyright (#PCDATA)>

<!ELEMENT image (title,link,url,width,height)>
<!ELEMENT url (#PCDATA)>
<!ELEMENT width (#PCDATA)>
<!ELEMENT height (#PCDATA)>

<!ELEMENT item (title,pubDate,link,author,comments,category,description)>
<!ELEMENT pubDate (#PCDATA)>
<!ELEMENT author (#PCDATA)>
<!ELEMENT comments (#PCDATA)>
<!ELEMENT category (#PCDATA)>
<!ELEMENT description (#PCDATA)>

]>
		<channel>
<title>Journal-of-Pharmaceutical-Research-Science-Technology-ISSUE VOLUME Volume 9 ISSUE Issue 1</title>
<link>http://ijpp.edwiserinternational.com/rss-feed.php</link>
<description>
Journal-of-Pharmaceutical-Research-Science-Technology: VOLUME Volume 9 ISSUE Issue 1, Jan-June 2025
</description>
<language>en-us</language>
<managingEditor>editor@edwiserinternational.com</managingEditor>
<webMaster>editor@edwiserinternational.com</webMaster>
<copyright>editor@edwiserinternational.com</copyright>
<image>
<title>Journal-of-Pharmaceutical-Research-Science-Technology-ISSUE VOLUME Volume 9 ISSUE Issue 1</title>
<link>http://ijpp.edwiserinternational.com/rss-feed.php</link>
<url>http://ijpp.edwiserinternational.com/img/logo1.png</url>
<width>360</width>
<height>109</height>
</image><item>
		<title>Drug-Prescription-Pattern-in-Patients-with-Rheumatoid-Arthritis-in-a-Tertiary-Care-Teaching-Hospital</title>
		<pubDate>15-May-2025</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/94qQCc.pdf</link>
		<author>Rajalakshmi-GR-Jayeshkumar-P-Anusree-AT-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Rheumatoid arthritis is a chronic autoimmune disorder that mostly affects joints. RA occurs when the immune system, which normally helps to protect the body from infectious diseases, attacks its own tissue. The disease causes pain, swelling, stiffness and loss of functions of the joint. Our study Drug prescription pattern in patients with Rheumatoid arthritis in a tertiary care teaching hospital (Cross-sectional study) aimed to identify the common medications prescribed for RA and to assess the ADRs associated with Anti- Rheumatoid drugs. This cross- sectional study was conducted in 121 patients who were given DMARD therapy. Patients demographic details, category of drugs used in the treatment, assessment of rationality of prescription, type of therapy (mono, dual or polytherapy) and causality assessment of ADRs of DMARDs were (Naranjo Algorithm) recorded. Our study concluded that the most commonly prescribed DMARDs was Methotrexate. According to demographic data out of 121 patients enrolled. Majority of them were females (91.73%, n=111) and only 8.26% n=10 male. Most of the patients belonged to the 41- 50 age group (n=35, 28.92%), only 2 patients belonged to the 11- 20 age group. Most of the RA patients were suffered from co- morbidities (n= 39, 32.2%), and 82 have no co- morbidities (n=82, 67.77%) and we observed that (prescription pattern of DMARDs) majorities of patients were received 2 DMARDs (n= 52, 42.97%) and 13 patients (n= 13, 10.74%) were received polytherapy. As per monotherapy, Methotrexate was given to majorities of the patients (n= 35, 67.3%) followed by HCQ (n= 13, 25%) Leflunomide (n= 3, 5.76%) and Sulfasalazine (n= 1, 1.9%). In dual therapy, Methotrexate (MTX) and HCQ were given to the majority of patients (n= 31, 55.3%) and in poly therapy MTX and HCQ and Sulfasalazine combinations were given to 9 patients (69.23% n=9).Other drugs given along with DMARDs are steroids (n= 96, 79.33%), NSAIDs (n= 40 33.05%) and supplementary drugs like folic acid was given to (n= 98, 80.99%) and PPIs were given to (n= 27, 22.3%) of patients. As per Naranjos Algorithm, 31 patients (n= 31 25.6%) had experienced ADR and 90 patients (n= 90, 74.3%) had experienced no ADR.]]>}</description>
		</item><item>
		<title>Simultaneous-Determination-of-Acetylsalicylic-Acid-Paracetamol-and-Ascorbic-Acid-in-Effervescent-Tablet-by-Different-Chemometric-Methods</title>
		<pubDate>08-Sep-2025</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/THcPtC.pdf</link>
		<author>Gzide-Pekcan</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[The spectrophotometric identification of acetylsalicylic acid, paracetamol, and ascorbic acid in the effervescent tablet.was investigated in this work. For acetylsalicylic acid, paracetamol, and ascorbic acid, chemometric analysis of the effervescent tablet.has proved successful. The spectrophotometric analysis of the effervescent tablet was done using the multivariate calibration methods: The multiple linear regression (UV-MLR) and The classical least squares approach (UV-CLS). Two spectrophotometric-chemometric methods were presented for the simultaneous prediction of the effervescent tablet in prepared mixes and pharmaceutical tablets without prior separation. The artificial mixtures were initially made with acetylsalicylic acid, paracetamol, and ascorbic acid, and the absorbance values were calculated using spectrophotometry. In the second stage, the amounts of common cold infection medications in the pharmaceutical tablets were calculated. Each medication's calibration curves are linear in the synthetic mix's concentration range. High recoveries and small standard deviations were determined, and the two techniques were evaluated for accuracy and repeatability. In the UV-MLR method, the SEC, PRESS, LOD and LOQ values were respectively; 0.032, 0.0040, 0.085, 0.283 for acetylsalicylic acid, 0.012, 0.0052, 0.091, 0.303 for paracetamol, 0,035, 0,0065, 0,084, 0,280 for ascorbic acid. In the UV-CLS method, the SEC, PRESS, LOD and LOQ values were respectively; 0.042, 0.0038, 0.057, 0.190 for acetylsalicylic acid, 0.025, 0.0057, 0.092, 0.307 for paracetamol, 0.054, 0.0058, 0.056, 0.187 for ascorbic acid.The applied chemometric approaches give quick, simple, and reliable findings. The proposed methods have been successfully used to identify the active compounds (acetylsalicylic acid, paracetamol, and ascorbic acid) in the effervescent tablet because they are very sensitive and accurate.]]>}</description>
		</item><item>
		<title>Spectrophotometric-Chemometric-Method-for-the-Quantitative-Determination-of-Two-Component-Cholesterol-Drugs</title>
		<pubDate>08-Sep-2025</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/hJk864.pdf</link>
		<author>Pekcan-G-Koak-K-Akta-AH-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[A novel spectrophotometric-chemometric approach has been developed for the concurrent quantitative determination of cholesterol-lowering drugs ezetimibe and simvastatin in pharmaceutical formulations. The proposed method integrates spectrophotometry with chemometric techniques, thereby enhancing analytical precision and accuracy. The spectral data were obtained in the ultraviolet-visible (UV-Vis) range and processed using multivariate calibration methods, including principal component regression (PCR) and partial least squares (PLS) regression.. This approach offers a cost-effective and efficient alternative for routine quality control and analysis of combination cholesterol therapies. In the case of simvastatin and ezetimibe, the solutions prepared for the analysis of their spectroscopic properties were prepared in a concentration range of 1-40 g/mL. The evaluation of the mean values and RMSD values has served as the foundation for determining the suitability of the analytical approach (0.0063; 0.008; 0.0018; 0.015). The calculated PRESS value is nearly negligible, thereby enhancing the degree of precision. The obtained PRESS values are sufficiently diminished (0.0082; 0.020; 0.0044; 0.010). The chemometric models effectively resolved the overlapping absorption spectra of ezetimibe and simvastatin, enabling their concurrent quantification without prior separation. The method was validated in accordance with ICH guidelines, demonstrating satisfactory linearity, sensitivity, and robustness. Application to commercial pharmaceutical samples yielded results consistent with labeled claims, confirming the method's reliability and practical applicability.]]>}</description>
		</item><item>
		<title>Dissolving-microneedles-an-advanced-approach-for-transdermal-drug-delivery</title>
		<pubDate>11-Sep-2025</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/j6k3tZ.pdf</link>
		<author>Tandon-S-Kumar-R-Singh-AP-et-al-</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[Dissolving microneedles (DMNs) are tiny, polymer-based needles designed for minimally invasive drug delivery. Traditionally, DMN arrays are mounted onto patches to aid their insertion into the skin. Microneedles are revolutionizing transdermal drug delivery by providing a minimally invasive and efficient way to administer therapeutic agents. These microscopic needlesavailable in solid, hollow, coated, and dissolving formswork by creating microchannels in the skin to enhance drug absorption. In contrast, dissolving microneedles (DMNs) offer superior drug-loading capabilities, easy fabrication, biodegradable properties, and the potential to be made entirely from the active pharmaceutical ingredient, eliminating the need for extra excipients. Microlancer, an innovative micropillar-based system that enables self-administration of DMNs. This novel approach ensures rapid and efficient drug delivery, achieving an impressive 97  2% delivery efficiency in less than a second, regardless of skin type or hair presence. This review explores the latest developments and future directions of DMNs, focusing on their advantages, challenges, and manufacturing techniques. The diverse applications of DMNs in areas such as cosmetics, vaccine delivery, diagnostics, cancer therapy, pain management, diabetes treatment, and dermatological disorders are discussed. Additionally, it highlights ongoing clinical trials, commercial advancements, and existing barriers to large-scale adoption, providing insight into the evolving landscape of dissolving microneedle technology. However, variations in skin elasticity and hair density often prevent complete insertion, leading to suboptimal drug delivery.]]>}</description>
		</item><item>
		<title>Thiazolidinone-derivatives-for-antimicrobial-activities-HPLC-method-development-and-validation</title>
		<pubDate>08-Sep-2025</pubDate>
<link>http://ijpp.edwiserinternational.com/admin/uploads/ypMO1X.pdf</link>
		<author>Kumari-P-Chourasiya-RK</author>
		<comments>{http://www.edwiserinternational.com/contact-us.php}</comments>
		<category>Pharmaceutical Science,Medical Science</category>
		<description>{<![CDATA[The global surge in antimicrobial resistance has intensified the need for novel therapeutic agents. Thiazolidinone derivatives, a class of heterocyclic compounds, have exhibited promising pharmacological properties, including antibacterial potential. This study reports the synthesis, analytical method development, validation, and antimicrobial evaluation of selected thiazolidinone derivatives. A reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed using a C18 column with an optimized mobile phase comprising acetonitrile and phosphate buffer (pH 4.0) under isocratic conditions. Detection was performed at 254 nm. The method was validated per ICH Q2(R1) guidelines, showing excellent specificity, linearity (R > 0.999), accuracy, precision (RSD < 2%), sensitivity, and robustness. The synthesized derivatives were screened for antimicrobial activity using disk diffusion and broth microdilution methods against Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans. Notably, TZD-3 exhibited strong antimicrobial activity (MIC as low as 24 g/mL) with good selectivity. The validated HPLC method ensures reliable quality control, and the derivatives present promising leads for further antimicrobial development.]]>}</description>
		</item></channel>